(Press-News.org) Scientists from the Center for Applied Medical Research (CIMA) of the University of Navarra (Spain) have discovered that cardiotrophin 1, a protein synthesized by muscle cells and adipose tissue, has a marked effect on fat and glucose metabolism. "These new findings add to those we already know on this compound such the anti-ischemic and cytoprotective effects showed in acute liver damage and solid organ transplants gives CT-1 great possibilities to be developed in various serious conditions", commented Pablo Ortiz, CEO of Digna Biotech.
The study was published in the August issue of Cell Metabolism, most prestigious journal in Metabolism and further details were described in the 25th August of SciBX, the Biocentury/Nature publication. The researchers found that the administration of cardiotrophin 1 accelerates the elimination of fat from the adipose tissue and increases the rate at which fat is burnt in muscles. Treatment of obese and diabetic mice with cardiotrophin 1 increases energy expenditure, reduces food intake and corrects obesity and diabetes. Investigators noticed that, in addition to its effects on fat metabolism, cardiotrophin 1 promotes the entrance of glucose into the cells and increases the sensitivity to insulin. The investigation has been led by M. Bustos, J. Prieto and MJ Moreno-Aliaga at CIMA.
Cardiotrophin 1 is co-developed for its use in organ transplantation and tissue regeneration by Digna Biotech and Biotecnol (The Consortium). Both of the companies signed an Exclusive License and Option Agreement with Genentech, Inc (a fully owned subsidiary of the Roche group) on September 2009. Pablo Ortiz remarked: "Cardiotrophin 1 showed a very interesting effect on fat metabolism which deserves to be explored in a clinical setting. We are ready to recruit healthy volunteers in the Phase I trial before the end of the year. Phase II in liver resection is scheduled for the second quarter of 2012. We are also confident that these new applications and the progress on the clinical development will allow us to forge partnerships with other biopharmaceutical companies to reach the patients as soon as possible". According to Pedro de Noronha Pissarra, CEO of Biotecnol: "expanding the use of such a promising molecule to other fields of use, where unmet needs exist, will build additional value to the current work. Its clear from the current findings on the mechanism of action of Cardiotrophin 1 in fat metabolism, that clinical work should be pursued and potentially new partnerships in order to expand such work can now be equated".
Pre-clinicial and clinical development of cardiotrophin 1 was funded by private and public Spanish entities: ClaveSuan, the Center for Industrial and Technological Development (CDTI), and the Government of Navarra. Only in liver resection and transplantation, cardiotrophin 1 may generate revenues of 350 millions of euros per year.
INFORMATION:
About Cardiotrophin 1 (CT-1)
Cardiotrophin 1 is a member of the interleukin-6 cytokine family. Recently, investigators from the Centre for Applied Medical Research (CIMA) have discovered that this protein is able to stimulate hepatic regeneration as well as to protect hepatocytes during clinical situations of acute hepatic damage. This means that CT-1 may be beneficial for those patients who undergo liver transplantation or extensive hepatic resection. The use of CT-1 in liver transplantation has already been granted Orphan Drug Status by both the FDA and the EMEA. In addition, cardiotrophin 1 has recently been shown to prevent graft injury and inflammatory response and prolong survival in animal kidney transplant model, and acute liver failure.
About Digna Biotech
Digna Biotech, a biotechnological company, is a spin-off of the University of Navarra (Pamplona, Spain) and is funded by a group of investors representing some of Spain's major corporations and financial institutions. It is committed to develop new drugs based on the IP generated by the Center for Applied Medical Research (CIMA) and to forge partnerships with pharmaceutical industry to ensure complete clinical development and commercial launch. Its extensive pipeline reflects the four major avenues of research pursued by CIMA: Cardiovascular, Gene Therapy, Hepatology and Oncology. Inspired by similar university-industry collaboration projects in USA, Digna Biotech presents a pioneering business model in Spain.. In cooperation with CIMA, CIFA (Center For Applied Pharmacobiology Research), a number of Schools of the University of Navarra (especially the School of Pharmacy and its Galenic Department), and the Clínica Universidad de Navarra, Digna Biotech is carrying out a range of activities to ensure the clinical trial development of the products. As a direct result of the company's commitment to translational research and focus on delivering meaningful health outcomes, and thanks to the effort made by the staff of Digna Biotech and CIMA, three products are now in the clinical phase. The company plans to enter a new product every year in clinical trials to reach the patient with innovative products for unmet medical needs. More information. www.dignabiotech.com and www.cima.es
About Biotecnol
Biotecnol is a biotechnology company developing biopharmaceutical products, and has a special focus on the development of novel antibody-based therapeutics to treat life-threatening diseases such as cancer. Biotecnol has a proprietary antibody format, which allows to develop multi-specific antibodies against various cancer targets. These formats are called Tribodies™. Biotecnol is committed in building value by developing
a diverse pipeline of antibody products to address unmet healthcare needs. Through its facilities in Portugal, Biotecnol leverages its business income by establishing in-house partner-led or collaborative programmes, which provide Biotecnol a strong client-based activity and an established track record. Biotecnol uses its proprietary expression technology, cell line development capabilities, upstream and downstream processing, analytics and QC experience for delivering therapeutic recombinant protein product and processes to support all stages of product development through early research and preclinical activities to GMP/GLP compliant processes for biomanufacturing of clinical and ultimately commercial products. More Information: www.biotecnol.com
END
CHESTNUT HILL, MA (9/13/2011) – Researchers from Boston College have developed a new class of small molecule receptors capable of detecting a lipid molecule that reveals the telltale signs of cellular death, particularly cancer cells targeted by anti-cancer drugs, the team reports in the current electronic edition of the Journal of the American Chemical Society.
Researchers led by Assistant Professor of Chemistry Jianmin Gao successfully grafted the key residues of the milk protein lactadherin onto the molecular scaffolding of a short but sturdy circular chain of amino ...
Manufacturing in Mexico has become the leading low-cost option available to companies seeking to nearshore facilities that have, until now, executed their production in distant Asian factories. Due to rising labor costs, reduced export tax credits, and ever higher costs of carrying inventory and executing transportation, an increasing number of firms are investigating the possibility of gaining economic advantage by moving operations in greater proximity to their home markets.
Manufacturing executives will be able to tour operating Mexico maquiladora operations at The ...
Parrenas offers a scholarly, sociological portrait of Filipina hostesses and waitresses in Tokyo's red-light districts that is clear and compelling enough for the lay reader... Parrenas illustrates why their diminishing numbers is not a "victory" in the global anti-trafficking campaign... To write this book, the author herself worked as a hostess in a Tokyo nightclub; her immersion in the world lends the book powerful authenticity.
- Publishers Weekly Review - 8/29/2011
In 2004, the U.S. State Department declared Filipina hostesses in Japan the largest group ...
PLAVEB, a Los Angeles, California based Web design and Web Development Company has an enviable projects portfolio, which is a testimonial of its successful track record in developing high performance web & mobile applications. Over the years, the company has worked on projects spanning various domains and has established itself as provider of unique and ground-breaking web & mobile solutions.
PLAVEB is focused on providing client specific solutions, through in-depth research and an end-user centric approach. This has guaranteed that the company's web design ...
Driftwagon will randomly pick a member to win this skateboard (a $250 value). The offer is open to any existing members or new invitees who officially become a member of Driftwagon's eCommerce site between now and September 15, 2011. The deck is made from reclaimed and sustainable maple flooring that is hand crafted to perfection. For the promotion, the deck has been paired with Independent trucks, Bones bearings, and McGill wheels. Soon after a lucky winner is picked, Driftwagon will have its first sale.
The online deal site has partnered with top brands in their industry ...
Suzanne Perry has paved the way to hope for victims and survivors of domestic violence by sharing her story and taking victim advocacy to the air, social networking, live stream and in-person. The efforts have paid off, with a virtual promotion to host the first interactive Global Forum on Domestic Violence.
Perry suffered 22 years of mental and physical bashing at the hands of her husband. After finally having him arrested, she decided she was going to break her silence.
Announced Tuesday, founder and producer of the eBroadcast Network, Charles Lewis appointed Perry ...
Glenn D. Prestwich, Director of the Therapeutic Biomaterials Center, Special Presidential Assistant for Faculty Entrepreneurism and Presidential Professor of Medicinal Chemistry at
University of Utah, will give a plenary keynote presentation on "Engineering a Clinical Biomaterial for Regenerative Medicine: From Bench to Business" at the 7th Modern Drug Discovery and Development Summit to be held in San Diego, CA on October 19-21, 2011 by GTC.
Faculty entrepreneurism is a scholarly activity. Dr. Prestwich will describe how the University of Utah has implemented ...
The Economic Development Collaborative-Ventura County recently appointed Tresa Wilkinson, vice president and CFO of the Fillmore and Western Railway, to its board of directors. Wilkinson will serve as a representative for the Santa Clara Valley region and brings with her key experience in the hospitality, tourism and transportation industries.
"In Ventura County, hospitality and tourism are extremely important to our economy's strength, so having Tresa's experience will be a great resource for us," said Bruce Stenslie, EDC-VC president and CEO. "She ...
Palomar Technologies, the world-leading provider of precision microelectronics and optoelectronic packaging systems, today announced that it will exhibit at SEMICON Taiwan 2011 in Taipei from September 7-9 in booth #1006.
The Palomar Technologies Asia-Pacific team has joined forces with Supremetec Materials, Inc. to offer the latest in high-accuracy die bonders and wire bonder systems at this year's tradeshow. Mr. PH Chan, Palomar Technologies' Asia-Pacific Director, will be on-site to discuss the latest advancements in systems and process development from Palomar Technologies.
"In ...
CCT Wireless has decided to join the fight against pediatric cancer by sponsoring the McDonald Hyundai Hope Charity Golf Tournament at the Blackstone Country Club in Aurora, Colorado benefiting the Children's Hospital in Denver.
CCT Wireless is a Sprint Preferred Retailer with numerous locations through Colorado. They offer a full line of the latest Sprint products and services. The company is known for their strong emphasis on superior customer service and highly trained wireless experts. They also have a clear dedication to their community and supporting a good cause. ...
